Slide 3
Image is not available
A platform company
Linking pharmaceutical innovation and
commercialization with strong product
lifecycle management capability
Slide 1
Image is not available
Committed to building a pharmaceutical
ecosystem focused on delivering solutions in
an open and collaborative setting for
the benefit of all stakeholders
To fulfill unmet clinical needs
Slide 2
Image is not available
Providing competitive
products and services
To enable the more effective diagnosis
and treatment, whilst enhancing clinical
practice to the ultimate benefit of the patient
previous arrow
next arrow

Innovation

Specialty-focused Innovative R&D Platform

Focusing on our advantageous specialty areas, targeting unmet clinical needs, we continuously identify and develop first-in-class (FIC) and best-in-class (BIC) innovative products. 

go

INNOVATION

Business

Specialty-Focused Commercialization Platform

Upholding clinical value as the core, we deliver competitive products and services that enhance disease diagnosis and treatment as well as clinical practice, ultimately benefiting patients.

go

BUSINESS

Cardio-cerebrovascular
and gastroenterology

Skin Health

Ophthalmology

Southeast Asia & the Middle East Business

News

2026-02-25

CMS Recognized in S&P Global Sustainability Yearbook for Second Consecutive Year

Recently, S&P Global, an internationally authoritative rating agency, has released the Sustainability Yearbook 2026 (the “Yearbook”). China Medical System (“CMS” or the “Group”) has stood out among 9,200 participating companies and successfully secured a place in the Yearbook, with a 2025 Corporate Sustainability Assessment (CSA) score of 66, surpassing 92% of global peers. This marks the second consecutive year that CMS has earned this international honor.   Source: S&P Global   Guided by its long-term ESG strategic objectives, CMS has deeply integrated the concept of sustainable development into its strategic decision-making and daily operations. The Group is driven by the dual engines of in-house R&D and collaborative R&D, continuously enhancing the accessibility and affordability of healthcare services and working to narrow health disparities across different regions and populations. Concurrently, we actively fulfill our corporate social responsibilities, leveraging innovative biotechnology to drive industry advancement and contribute to the sustained improvement of social well-being. Our sustainability performance has also been recognized by multiple authoritative rating agencies: MSCI ESG Rating maintained at “AA”; the Hong Kong […]

go
战略合作&联系我们

Partnering

We collaborate with global innovative companies in flexible structures to jointly build a pharmaceutical ecosystem in a sustainable and collaborative setting for the benefit of all stakeholders.

go

Contact Us

If you are interested in joining us, or curious about our business and products, please feel free to contact us.

go